Enhanced analgesic effect of morphine-nimodipine combination
after intraspinal administration as compared to systemic
administration in mice§
DILIP VERMA, SUBRATA BASU RAY†, ISHAN PATRO* and SHASHI WADHWA
Department of Anatomy, All India Institute of Medical Sciences, New Delhi 110 029, India
*Neuroscience Centre, Jiwaji University, Gwalior 474 011, India
†
Corresponding author (Fax, 91-11-26588663; Email, sbr_aiims@hotmail.com)
Calcium plays an important role in the pathophysiology of pain. A number of studies have investigated the effect of
L-type calcium channel blockers on the analgesic response of morphine. However, the results are conflicting. In
the present study, the antinociceptive effect of morphine (2⋅5 µg) and nimodipine (1 µg) co-administered intraspinally in mice was observed using the tail flick test. It was compared to the analgesic effect of these drugs
(morphine – 250 µg subcutaneously; nimodipine – 100 µg intraperitoneally) after systemic administration. Nimodipine is highly lipophilic and readily crosses the blood brain barrier. Addition of nimodipine to morphine
potentiated the analgesic response of the latter when administered through the intraspinal route but not when
administered through systemic route. It may be due to direct inhibitory effect of morphine and nimodipine on
neurons of superficial laminae of the spinal cord after binding to µ-opioid receptors and L-type calcium channels
respectively.
[Verma D, Ray S B, Patro I and Wadhwa S 2005 Enhanced analgesic effect of morphine-nimodipine combination after intraspinal administration as compared to systemic administration in mice; J. Biosci. 30 491–497]
1.
Introduction
Calcium plays an important role in the transmission of
pain signals in the central nervous system. At the presynaptic nerve terminal, voltage-gated calcium channels
(VGCCs) open in response to action potentials to allow
an influx of calcium ions. The influx is a graded process
varying in a linear manner with the frequency of action
potentials. The influx, in turn, leads to release of various
neurotransmitters that diffuse across the synaptic cleft to
the postsynaptic membrane and binds to their specific
receptors. Morphine is the drug of choice for treatment of
chronic pain (McCarberg and Barkin 2001). It binds to µopioid receptor (MOR) on the pre- and postsynaptic
membranes. However, administration of morphine also
produces serious side effects like tolerance and dependence, which limits its long-term use. The exact underlying
reasons for tolerance and dependence are not definitively
known (Ray and Wadhwa 2001).
Binding of morphine to MOR leads to inhibition of
neurons concerned with transmission of pain. MOR does
so by blocking VGCCs, opening inwardly rectifying
potassium channels and inhibiting activity of adenylyl
cyclase (North 1993). The release of pain producing neurotransmitters like substance P from the presynaptic terminals in the spinal cord is thereby decreased leading to
relief from pain (Smith et al 2002).
Since their discovery, VGCCs have been the subject of
intense investigation (Fatt and Katz 1953). Six varieties
of calcium channels (L-, N-, P-, Q-, R- and T-types) have
Keywords. Intraspinal; morphine; nimodipine; tail flick latency
________________
§
Patent applied for.
Abbreviations used: CCBs, Calcium channel blockers; MOR, µ-opioid receptor; MPE, maximum permissible effect; VGCCs,
voltage-gated calcium channels.
http://www.ias.ac.in/jbiosci
J. Biosci. 30(4), September 2005, 491–497, © Indian Academy of Sciences
491
492
Dilip Verma et al
been demonstarted in neurons (Catterall 2000). Among
these, the L- and N-types are responsible for neurotransmitter release from sensory neurons of the dorsal column
of spinal cord (Nowycky et al 1985). A number of studies
have shown an increase in analgesic response of opioids
like morphine, when co-administered with L-type calcium channel blockers (CCBs) (Contreras et al 1988;
Carta et al 1990; Dierssen et al 1990; Omote et al 1993;
Neugebauer et al 1996; Santillan et al 1998). Contrary to
this, other reports have found no beneficial effect (Roca
et al 1996; Hasegawa and Zacny 1997; Diaz and Dickenson
1997; Sluka 1998). Thus, the present study was undertaken to observe the effect of nimodipine, a L-type CCB,
on morphine-induced analgesia, both after intraspinal
(intrathecal) and systemic administration in mice. The
dose of morphine and nimodipine administered intraspinally was 2⋅5 µg and 1 µg. However, the doses of the
same drugs were increased by 100 times for systemic
administration to compensate for increased volume of
distribution. Nimodipine is highly lipophilic and crosses
the blood brain barrier in contrast to other CCBs. A potentiation of analgesic effect of morphine would help in
lowering the dose of morphine. This would bring about a
corresponding decrease of side effects. This is the first
report on the interaction between morphine and nimodipine
after intraspinal administration.
2.
Methods
Male mice of Swiss strain (n = 46) weighing between 20–
25 g were procured from the experimental animal facility
of All India Institute of Medical Sciences. Prior approval
of the Institutional Animal Ethics Committee of AIIMS was
obtained. The animals were housed in well-ventilated
cages with food and water given ad libitum. Twelve hour
light and dark cycles were maintained.
2.1 Drug administration
The animals were divided into six groups – I to VI (G IVI). G I (n = 6) received 2⋅5 µg of morphine intraspinally, G II (n = 8) received a combination of 2⋅5 µg of
morphine and 1 µg of nimodipine intraspinally, G III
(n = 9) received morphine (10 mg/kg) subcutaneously
while G IV (n = 7) received morphine (10 mg/kg) subcutaneously and (10 mg/kg) nimodipine intraperitoneally.
In G IV, nimodipine was administered 20 min before
morphine. Only nimodipine (1 µg) was also injected intraspinally into a group (G V) of mice (n = 5). A separate
group (G VI) of mice (n = 6) received nimodipine (10 mg/
kg) intraperitoneally. Normal saline was also injected
intraspinally (n = 5). The amount of morphine injected
intrathecally was about 1 : 100 of that injected subcutaJ. Biosci. 30(4), September 2005
neously. Intrathecal injections were given into the spine
in the midline (between L5 and L6 vertebrae) in unanaesthesized mice using previously standardized technique
(Hylden and Wilcox 1980). The total volume injected
intrathecally was 10 µl. Subcutaneous injections were
given in one of the hind limbs.
2.2 Assessment of sensitivity to noxious thermal stimuli
The analgesic response was measured by the tail flick
apparatus (UGO Basile). The animal was placed in a restrainer with its tail outside. The tail (distal 1/3rd) was
exposed to an infrared source of radiation. The animal
flicks its tail away from the source of heat on feeling
pain. Baseline latency for the tail flick was recorded at
the beginning of the experiment and was within 2–4⋅5 s.
Analgesic drugs like morphine delay the response time in
a dose-dependent manner. However, if there was no response within 10 s, the animal was removed to prevent
damage to the tail (cut off time). The maximum permissible
effect (MPE) was calculated from the values of tail flick
test using the following formula: % MPE = [(observed
latency-baseline latency)/(cut off time – baseline latency)] ×
100.
The tail flick latency was measured after 15 and 30 min
of morphine and/or nimodipine administration. Subsequently it was measured every 30 min till 5 h in G I and
II and 3⋅5 h in G III and IV.
Statistical evaluation was done using ANOVA with
post hoc multiple comparisons between groups I–IV only.
P < 0⋅05 was considered significant. Results of tail flick
response from each group were calculated as mean ±
standard error of mean.
2.3
Drugs
Morphine sulphate IP ampoules were purchased from
Govt. Pharmacy after permission from Narcotic Commissioner. It was diluted in normal saline IP to obtain desired
concentration. Nimodipine was obtained from Sigma,
USA. It was dissolved in a solution containing polyethylene
glycol, physiological saline and absolute alcohol in 2 : 2 : 1
ratio under subdued lighting, as nimodipine is light sensitive.
3.
3.1
Results
General observations
The analgesic response was evident within 15 min of
administration of morphine (figure 1). Addition of nimodipine produced 100% response as compared to morphine
alone, after both intraspinal and systemic administration
493
Analgesia after morphine-nimodipine administration
at 15 min (figure 2). The rate of decrease of analgesia
was also less, when nimodipine was co-administered
(G II and IV). Even after 5 h of administration, the MPE
in G II was 37⋅5% as compared to G I (12⋅29%).
3.2
Between-group comparison
Addition of nimodipine to morphine increased the analgesic
effect of morphine when given intraspinally (G I and II;
figure 1, table 1). The tail flick latency in G II showed a
significant increase (P < 0⋅05 at 2, 2⋅5 and 3 h). Maximum analgesia was seen as early as 15 min after administration. The analgesic response of subcutaneous morphine
along with intraperitoneal nimodipine showed an increase
but it was not statistically significant at any time point
(G III and IV). Only nimodipine groups (G V and VI) did
not show any analgesic response. None of the rats showed
any signs of motor paralysis (intact stepping reflex and
righting reflex). The saline group showed values close to
the baseline.
4.
Discussion
Previous reports indicate that intraspinal administration
of morphine produces potent analgesia in the postoperative
period (Cousins and Mather 1984; Domsky and Kwartowitz 1992). However, distressing side effects like pruritus,
urinary incontinence, nausea and delayed respiratory depression may complicate its use, particularly in the elderly
(Slappendel et al 2000; Goodarzi and Narasimhan 2001).
In order to reduce the incidence of side effects, the
amount of morphine must be kept to the minimum. One
way to do this would be to combine it with other drugs so
as to achieve a potentiation of the analgesic effect of
morphine. Thus, in the present study, the analgesic effect
of morphine-nimodipine combination was investigated.
12
morphine(i.t.)
morphine+nimodipine(i.t.)
morphine(s.c.)
Tail Flick Threshold(sec)
10
morphine(s.c.)+nimodipine(i.p.)
8
6
4
2
0
0
15
30
60
90
120*
150* 180*
210
240
270
300
Time (min)
Figure 1. The time course of tail flick latency after intraspinal morphine (G I), intraspinal morphine + nimodipine
(G II), subcutaneous morphine (G III) and subcutaneous morphine + intraperitoneal nimodipine (G IV) administration.
Significantly higher threshold (marked with*) was noted in G II as compared all other groups at 2, 2⋅5 and 3 h
(P < 0⋅05).
J. Biosci. 30(4), September 2005
494
Dilip Verma et al
Table 1. The mean, standard error, minimum and maximum values of tail flick latency for all the groups (G I–VII) have been
shown. The time period for which values of tail flick latency were recorded was one hour for G V–VII.
Time
Groups
0:00
GI
G II
G III
G IV
GV
G VI
G VII
GI
G II
G III
G IV
GV
G VI
G VII
GI
G II
G III
G IV
GV
G VI
G VII
GI
G II
G III
G IV
GV
G VI
G VII
GI
G II
G III
G IV
GI
G II
G III
G IV
GI
G II
G III
G IV
GI
G II
G III
G IV
GI
G II
G III
G IV
GI
G II
G III
G IV
GI
G II
G III
G IV
GI
G II
G III
G IV
0:15
0:30
1:00
1:30
2:00
2:30
3:00
3:30
4:00
4:30
5:00
Number of animals
Mean
Standard error
Minimum values
Maximum values
6
8
9
7
5
6
5
6
8
9
7
5
6
5
6
8
9
7
5
6
5
6
8
9
7
5
6
5
6
8
9
7
6
8
9
7
6
8
9
7
6
8
9
7
6
8
9
7
6
8
9
7
6
8
9
7
6
8
9
7
2⋅4
2⋅5
2⋅9
2⋅9
2⋅8
3⋅4
3⋅1
9⋅3
10⋅0
9⋅6
10⋅0
2⋅6
2⋅9
3⋅3
8⋅5
9⋅0
9⋅5
10⋅0
3⋅3
2⋅8
3⋅4
8⋅0
10⋅0
8⋅8
9⋅3
2⋅6
3⋅3
3⋅7
7⋅1
9⋅2
7⋅6
8⋅9
6⋅0
9⋅0
4⋅5
5⋅3
6⋅4
8⋅5
4⋅2
4⋅7
5⋅0
7⋅5
3⋅3
4⋅3
6⋅3
7⋅8
2⋅8
3⋅6
4⋅6
6⋅8
–
–
3⋅9
5⋅5
–
–
3⋅3
4⋅6
–
–
0⋅05
0⋅07
0⋅26
0⋅21
0⋅17
0⋅27
0⋅14
0⋅62
0⋅00
0⋅17
0⋅00
0⋅19
0⋅23
0⋅26
0⋅74
0⋅45
0⋅14
0⋅00
0⋅27
0⋅17
0⋅46
0⋅97
0⋅00
0⋅56
0⋅56
0⋅46
0⋅26
0⋅24
0⋅91
0⋅53
0⋅64
0⋅78
0⋅90
0⋅45
0⋅78
0⋅49
0⋅98
1⋅0
0⋅58
0⋅66
1⋅2
1⋅0
0⋅43
0⋅44
1⋅3
1⋅0
0⋅26
0⋅53
0⋅62
1⋅0
–
–
0⋅74
1⋅0
–
–
0⋅11
0⋅55
–
–
2⋅2
2⋅2
1⋅8
2⋅2
2⋅3
2⋅8
2⋅8
6⋅0
10⋅0
9⋅0
10⋅0
2⋅2
2⋅0
2⋅8
5⋅9
6⋅4
9⋅0
10⋅0
2⋅5
2⋅2
2⋅6
5⋅0
10⋅0
5⋅0
6⋅0
1⋅6
2⋅5
3⋅4
5⋅3
5⋅6
4⋅5
4⋅6
3⋅8
6⋅4
1⋅8
3⋅8
4⋅1
2⋅5
2⋅6
2⋅8
3⋅0
3⋅0
2⋅0
2⋅0
2⋅6
2⋅6
1⋅3
2⋅2
3⋅1
3⋅3
–
–
2⋅7
2⋅4
–
–
3⋅2
3⋅0
–
–
2⋅5
2⋅9
4⋅1
3⋅8
3⋅1
4⋅4
3⋅3
10⋅0
10⋅0
10⋅0
10⋅0
3⋅1
3⋅6
3⋅7
10⋅0
10⋅0
10⋅0
10⋅0
3⋅8
3⋅5
4⋅2
10⋅0
10⋅0
10⋅0
10⋅0
3⋅8
4⋅0
4⋅2
10⋅0
10⋅0
10⋅0
10⋅0
10⋅0
10⋅0
10⋅0
7⋅4
10⋅0
10⋅0
8⋅4
7⋅8
10⋅0
10⋅0
6⋅0
6⋅0
10⋅0
10⋅0
3⋅9
5⋅7
6⋅8
10⋅0
–
–
6⋅8
10⋅0
–
–
3⋅7
6⋅6
–
–
J. Biosci. 30(4), September 2005
495
Analgesia after morphine-nimodipine administration
The results of the present study indicate that nimodipine
increases the analgesic effect of morphine. Moreover, the
intraspinal route appears to be better than systemic administration presumably due to the absence of dilution
within the blood. The dose required is also 1/100th less.
Considering the various types of calcium channels and
their blockers, some degree of uncertainty persists regarding the efficacy of various CCBs, when given along
with morphine (Venegas and Schaible 2000). The reason
may be that presynaptic terminals from even the same
axon possess different calcium channels mediating release of neurotransmitters, described as a functional patchwork (Reid et al 2003). Earlier studies have shown a
superior analgesic effect resulting from combination of
morphine with L-type CCBs in experimental animals
when given intrathecally (Omote et al 1993; Dogrul et al
2001). Even analgesic effect has been noted with only
CCBs without morphine on intrathecal administration,
though it was of short duration (15 min) and sometimes
associated with motor paralysis (Hara et al 1998). In the
present study, no analgesic effect was observed with only
nimodipine, probably due to its low dose. Nimodipine
has been shown to facilitate pain relief in combination
with morphine in patients suffering from cancer, when
given orally (Santillan et al 1998). Further, nimodipine
could prevent the escalation of morphine dosage in a statistically significant manner without any major side effects
(dyspepsia being the commonest).
To the best of our knowledge, all of the experimental
studies on the analgesic effect of morphine in combination
with L-CCBs have recorded pain sensitivity up to 3 h.
However, in the present study, a higher analgesic effect
of morphine-nimodipine combination was observed even
at 5 h after intraspinal administration as compared to
morphine alone (figure 2). Remarkably, more than 1/3rd
of the peak analgesic effect persisted in G II at 5 h. In a
clinical scenario, this can make a difference between tolerable and intolerable pain. It was also persistently higher
throughout the period of observation (15 min to 5 h).
Thus the combination had an enhanced effect (synergistic
response) while nimodipine by itself did not have
an analgesic effect. Further, another dihydropyridine,
amlodipine had a similar potentiative effect on morphine
throughout the period of observation for 1 h (Dogrul
et al 2001). But the dose of amlodipine injected into individual rats was 10 µg, which was comparatively much
higher than in the present study. Nimodipine is used for
treatment of hypertension. A previous study did not find
any evidence of systemic hypotension after intrathecal
administration of 50 µg of nimodipine nor any alteration
in the blood flow within the spinal cord (Imamura
and Tator 1998). Presumably, these side effects of
nimodipine were absent in the present study as the dose
of nimodipine injected intraspinally was 1 µg. It is possible that after systemic administration of morphinenimodipine combination, reduced blood flow to the spinal
morphine(i.t.)
100
morphine+nimodipine(i.t.)
morphine(s.c.)
morphine(s.c.)+nimodipine(i.p.)
Tail Flick Threshold(sec)
80
60
40
20
0
0
-20
Figure 2.
60
150
240
300
Time(min)
Maximum permissible effect (MPE) observed in G I–IV at different time points as in figure 1.
J. Biosci. 30(4), September 2005
496
Dilip Verma et al
cord and brain may have decreased the analgesic efficacy
of this combination.
Some studies have reported synergistic effect between
morphine and N-type CCBs (Omote et al 1996; Wang et al
2000). Particularly, ziconotide – a synthetic analogue of
ω-conotoxin MVIIA – is being used for treatment of
neuropathic pain. A related peptide CVID, also known as
AM336, has been reported to have a larger therapeutic
window as compared to ziconotide (Smith et al 2002).
However, neurological side effects are common with Ntype CCBs.
A recent report has shown the relative functional importance of different VDCCs in neurons of lamina I of
the rat spinal cord (Heinke et al 2004). An inhibition of
postsynaptic current was observed with L-type CCB
(verapamil) after electrical stimulation of dorsal nerve
root. However, maximum inhibition was observed with
N-type CCB (ω-conotoxin GVIA). It is possible that intraspinal nimodipine could have potentiated the action of
morphine by a similar mechanism in the present study.
Neurons of laminae I and II also show higher expression
of MOR (Ray et al 2005). Thus, morphine could directly
bind to MOR after intraspinal administration and decrease neuronal excitability. Apart from pharmacokinetic
factors, pharmacodynamic factors also play a role in the
synergistic interaction between morphine and nimodipine. A recent study has shown that prior administration of
CCBs (diltiazem, nimodipine and verapamil belonging to
benzothiazepine, dihydropyridine and phenylalkylamine
classes respectively) to morphine significantly increased
the concentration of the morphine in the serum after systemic administration (Shimizu et al 2004). The increased
concentration of morphine in the serum produced a statistically significant increase in its analgesic effect. On systemic administration of morphine and nimodipine, we
also observed a higher analgesic effect though it was not
statistically significant. These may be explained by the
different experimental conditions. Interestingly, some of
the CCBs (diltiazem and verapamil) also increase morphine levels in the brain when co-administered together,
as compared to morphine alone, after systemic administration (Shimizu et al 2004). Thus, combinations of
morphine and CCBs represent exciting clinical entities in
the near future.
In conclusion, the present study highlights the greater
analgesic effect obtained with combination of morphine
and nimodipine as compared to morphine alone after intraspinal administration.
Acknowledgement
This study was financially supported by an Intramural
research grant from the All India Institute of Medical
Sciences, New Delhi.
J. Biosci. 30(4), September 2005
References
Carta F, Bianchi M and Argenton S 1990 Effect of nifedipine
on morphine-induced analgesia; Anesthesiol. Analg. 70 493–
498
Catterall W A 2000 Structure and regulation of voltage-gated
Ca2+ channels; Annu. Rev. Cell Dev. Biol. 16 521–555
Contreras E, Tamayo L and Amigo M 1988 Calcium channel
antagonists increase morphine-induced analgesia and antagonize morphine tolerance; Eur. J. Pharmacol. 148 463–466
Cousins M J and Mather L E 1984 Intrathecal and epidural
administration of opioids; Anesthesiology 17 276–310
Diaz A and Dickenson A H 1997 Blockade of spinal N- and Ptype, but not L-type, calcium channels inhibits the excitability of rat dorsal horn neurons reduced by subcutaneous formalin inflammation; Pain 69 93–100
Dierssen M, Florez J and Hurle M A 1990 Calcium channel
modulation by dihydropyridines modifies sufentanil-induced
antinociception in acute and tolerant conditions; NaunynSchmiedebergs Arch. Pharmakol. 342 559–565
Dogrul Ö Y, Isimer A and Guzeldemir M E 2001 L-type and Ttype calcium channel blockade potentiate the analgesic effects of morphine and selective µ-opioid agonist, but not to
selective δ and κ agonists at the level of spinal cord in mice;
Pain 93 61–68
Domsky M and Kwartowitz J 1992 Efficacy of subarachnoid
morphine in a community hospital; Reg. Anesthesiol. 17
279–282
Fatt P and Katz B 1953 The electrical properties of crustacean
muscle fibres; J. Physiol. 120 171–204
Goodarzi M and Narasimhan R R 2001 The effect of large-dose
intrathecal opioids on the autonomic nervous system; Anesthesiol. Analg. 93 456–459
Hara K, Saito Y, Kirihara Y, Sakura S and Kosaka Y 1998
Antinociceptive effects of intrathecal L-type Calcium channel blockers on visceral and somatic stimuli in the rat; Anesthesiol. Analg. 87 382–387
Hasegawa A E and Zancy J P 1997 The influence of three Ltype channel blockers on morphine effects in healthy volunteers; Anesthesiol. Analg. 85 633–638
Heinke A, Balzer E and Sandkuhler J 2004 Pre- and postsynaptic
contributions of voltage-dependent Ca2+ channels to nociceptive
transmission in rat spinal lamina I neurons; Eur. J. Neurosci.
19 103–111
Hylden J L K and Wilcox G L 1980 Intrathecal morphine in
mice: a new technique; Eur. J. Pharmacol. 67 313–316
Imamura H and Tator C H 1998 Effect of intrathecal nimodipine
on spinal cord blood flow and evoked potentials in the normal or injured cord; Spinal Cord 36 497–506
McCarberg B H and Barkin R L 2001 Long-acting opioids for
chronic pain: pharmacotherapeutic opportunities to enhance
complaince, quality of life, and analgesia; Am. J. Therapeutics 8 181–186
Neugebauer V, Vanegas H, Nebe J, Rumenapp P and Schaible
H-G 1996 Effects of N- and L-type calcium channel antagonists
on the responses of nociceptive spinal cord neurons to mechanical stimulation of the normal and inflamed knee joint;
J. Neurophysiol. 76 3740–3749
North R A 1993 Opioid actions on membrane ion channels;
in Opioids I (ed.) A Hertz (New York: Springer) pp 773–
797
Nowycky M C, Fox A P amd Tsien R W 1985 Three types of
neuronal calcium channel with different calcium agonist sensitivity; Nature (London) 316 440–443
Analgesia after morphine-nimodipine administration
Omote K, Kawamata M, Satoh O, Iwasaki H and Namiki A
1996 Spinal antinociceptive action of an N-type voltagedependent calcium channel blocker and the synergistic interaction with morphine; Anesthesiology 84 636–643
Omote K, Sonoda H, Kawamata M, Ivasaki H and Namiki A
1993 Potentiation of antinociceptive effects of morphine by
calcium-channel blockers at the level of spinal cord; Anaesthesiology 79 746–752
Ray S B and Wadhwa S 2001 The enigma of morphine tolerance: recent insights; J. Biosci. 26 555–559
Ray S B, Gupta Y K and Wadhwa S 2005 Expression of opioid
receptor-like 1 (ORL1) and mu opioid receptors in the spinal cord
of morphine tolerant mice; Indian J. Med. Res. 121 194–202
Reid C A, Bekkers J M and Clements J D 2003 Presynaptic
Ca2+ channels: a functional patchwork; Trends Neurosci. 26
683–687
Roca G, Aguilar J L, Gomar G, Mazo V, Costa J and Vidal F
1996 Nimodipine fails to enhance the analgesic effect of
slow release morphine in the early phases of cancer pain
treatment; Pain 68 239–243
Santillan R, Hurle M A, Armijo J A, Mozos R D and Florez J
1998 Nimodipine-enhanced opiate analgesia in cancer patients requiring morphine dose escalation: a double-blind,
placebo-controlled study; Pain 76 17–26
497
Shimizu N, Kishioka S, Maeda T, Fukazawa Y, Yamamoto C,
Ozaki M and Yamamoto H 2004 Role of pharmacokinetic effects in the potentiation of morphine analgesia by L-type calcium channel blockers in mice; J. Pharmacol. Sci. 94 240–
245
Slappendel R, Weber E W G and Benraad B 2000 Itching after
intrathecal morphine: incidence and treatment; Eur. J. Anaesthesiol. 17 616–621
Sluka K A 1998 Blockade of N- and P/Q-type calcium channels
reduces the secondary heat hyperalgesia induced by acute inflammation; J. Pharmacol. Exp. Therap. 28 232–237
Smith M T, Cabot P J, Ross F B, Robertson A D and Lewis R J
2002 The novel N-type calcium channel blocker, AM336,
produces potent dose-dependent antinociception after intrathecal dosing in rats and inhibits substance P release in rat
spinal cord slices; Pain 96 119–127
Venegas H and Schaible H 2000 Effect of antagonists to high
threshold calcium channels upon spinal mechanism on pain,
hyperalgesia and allodynia; Pain 85 9–18
Wang Y X, Gao D, Pettus M, Phillips C and Bowersox S S
2000 Interactions of intrathecally administered ziconotide, a
selective blocker of neuronal N-type voltage-sensitive calcium channels, with morphine on nociception in rats; Pain 84
271–281
MS received 23 November 2004; accepted 13 June 2005
ePublication: 28 July 2005
Corresponding editor: INDRANEEL MITTRA
J. Biosci. 30(4), September 2005